Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RNA 
Avidity Biosciences Inc (RNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: RNA (3-star) is a SELL. SELL since 1 days. Simulated Profits (22.75%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $68.94
1 Year Target Price $68.94
| 9 | Strong Buy |
| 6 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 261.42% | Avg. Invested days 36 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.78B USD | Price to earnings Ratio - | 1Y Target Price 68.94 |
Price to earnings Ratio - | 1Y Target Price 68.94 | ||
Volume (30-day avg) 15 | Beta 0.99 | 52 Weeks Range 21.51 - 56.00 | Updated Date 09/16/2025 |
52 Weeks Range 21.51 - 56.00 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4448.71% |
Management Effectiveness
Return on Assets (TTM) -24.01% | Return on Equity (TTM) -37.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4577941297 | Price to Sales(TTM) 538.51 |
Enterprise Value 4577941297 | Price to Sales(TTM) 538.51 | ||
Enterprise Value to Revenue 426.69 | Enterprise Value to EBITDA -5.72 | Shares Outstanding 143652992 | Shares Floating 107830794 |
Shares Outstanding 143652992 | Shares Floating 107830794 | ||
Percent Insiders 4.53 | Percent Institutions 101.77 |
Upturn AI SWOT
Avidity Biosciences Inc
Company Overview
History and Background
Avidity Biosciences, Inc. was founded in 2012. It is a biopharmaceutical company pioneering Antibody Oligonucleotide Conjugates (AOCs) to treat diseases with unmet needs. The company went public in 2020 and is focused on developing therapies for muscle diseases and other serious conditions.
Core Business Areas
- AOC Platform Development: Avidity's primary business is the development of its proprietary AOC platform. This involves designing and synthesizing AOCs to target specific tissues and deliver therapeutic oligonucleotides.
- Drug Development: The company focuses on researching, developing, and commercializing AOC therapeutics for a range of indications, mainly focused on muscle disorders.
Leadership and Structure
Sarah Boyce serves as the President and CEO. The organizational structure includes research & development, clinical development, and commercial operations, overseen by a board of directors.
Top Products and Market Share
Key Offerings
- AOC 1001 (DMD): AOC 1001 is Avidity's lead product candidate targeting Duchenne Muscular Dystrophy (DMD) amenable to exon 51 skipping. It is currently in clinical development. Competitors in the DMD gene therapy space include Sarepta Therapeutics (SRPT) and Solid Biosciences (SLDB).
- AOC 1044 (DM1): AOC 1044 targets Myotonic Dystrophy Type 1 (DM1). This is another key program in clinical development. Ionis Pharmaceuticals (IONS) is a competitor targeting similar diseases.
Market Dynamics
Industry Overview
The industry is characterized by rapid innovation in oligonucleotide therapeutics and targeted drug delivery. There is increasing investment and competition in rare disease treatments.
Positioning
Avidity is a leader in AOC technology and is focused on expanding the applications of this platform. Its competitive advantage lies in its proprietary AOC platform, which allows for precise targeting and efficient delivery of oligonucleotide therapeutics.
Total Addressable Market (TAM)
The total addressable market for oligonucleotide therapeutics is estimated to be in the billions of dollars and is expanding rapidly. Avidity is well-positioned to capture a significant portion of this market through its AOC platform and pipeline of drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary AOC platform technology
- Strong intellectual property portfolio
- Experienced management team
- Clinical-stage pipeline
- Strong partnerships and collaborations
Weaknesses
- Dependence on AOC platform success
- Limited commercialization experience
- High R&D expenses
- Susceptible to clinical trial setbacks
- Competition from established pharmaceutical companies
Opportunities
- Expansion of AOC platform to new indications
- Strategic partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Regulatory approvals for lead product candidates
- Growing demand for targeted therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other oligonucleotide therapies
- Patent challenges
- Economic downturn affecting R&D investment
Competitors and Market Share
Key Competitors
- SRPT
- IONS
- SLDB
Competitive Landscape
Avidity's AOC platform offers a unique approach to targeted drug delivery. It competes with established gene therapy and oligonucleotide therapy companies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by advancements in its clinical programs and expansion of the AOC platform.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization success. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing AOC 1001 and AOC 1044 into later-stage clinical trials and exploring new AOC targets.
Summary
Avidity Biosciences is a biopharmaceutical company pioneering AOCs with a promising platform technology and clinical-stage pipeline focusing on muscle disorders. Its strengths lie in its innovative AOC platform, but it faces challenges related to clinical trial risks and competition. Successfully navigating regulatory hurdles and achieving positive clinical trial outcomes are crucial for future growth. The company needs to demonstrate its clinical data in order to gain market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Avidity Biosciences Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Actual results may vary. Investments in biotechnology companies are inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avidity Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2013-06-28 | President, CEO & Director Ms. Sarah Boyce | ||
Sector Healthcare | Industry Biotechnology | Full time employees 391 | |
Full time employees 391 | |||
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.